Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2272-2283

  Harrison, Simon J ^a,b   Franklin, Ian M ^b   Campbell, John D M ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Dendritic cell; Immunotherapy; Monoclonal gammopathy of uncertain significance; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; THALIDOMIDE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER RELAPSE; CELL ASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PLASMACYTOMA; PRIORITY JOURNAL;

AGED; B-LYMPHOCYTES; BLOOD CELL COUNT; CASE-CONTROL STUDIES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; PLASMACYTOMA;

EID: 57449089714     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802464729     Document Type: Article

References (49)

1. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol, 121, pp. 749-757.
2. Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E. Hawkins, K. et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [see comment]. N Engl J Med, 348, pp. 1875-1883.
3. Attal, M. and Harousseau, J. L. (1999) Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol, 12, pp. 171-191.
4. Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M. Palumbo, A. et al. (1999) Molecular and clinical remission in multiple myeloma: role of autologous and allogeneic transplantation of haematopoietic cells. J Clin Oncol, 17, pp. 208-215.
5. Bensinger, W., Buckner, C., Anasetti, C., Clift, R., Storb, R., Barnett, T. Chauncey, T. et al. (1996) Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood, 88, pp. 2787-2793.
6. Verdonck, L. F., Petersen, E. J., Lokhorst, H. M., Nieuwenhuis, H. K., Dekker, A. W. Tilanus, M. G. et al. (1998) Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells. Bone Marrow Transplant, 22, pp. 1057-1063.
7. Tricot, G., Vesole, D. H., Jaganath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) Graft-versus-myeloma effect: Proof of principle. Blood, 87, pp. 1196-1199.
8. Perez-Simon, J. A., Martino, R., Alegre, A., Tomas, J. F., De Leon, A. Caballero, D. et al. (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol, 121, pp. 104-108.
9. Crawley, C., Lalancette, M., Szydlo, R., Gilleece, M., Peggs, K. Mackinnon, S. et al. (2005) Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 105, pp. 4532-4539.
10. Harrison, S. J., Cook, G., Nibbs, R. J. and Prince, H. M. (2006) Immunotherapy of multiple myeloma: The start of a long and tortuous journey. Expert Rev Anticancer Ther, 6, pp. 1769-1785.
11. Cook, G. and Campbell, J. D. (1999) Immune regulation in multiple myeloma: The host-tumour conflict. Blood Rev, 13, pp. 151-162.
12. Brown, R., Murray, A., Pope, B., Sze, D. M., Gibson, J. Ho, P. J. et al. (2004) Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol, 125, pp. 743-748.
13. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G. Ludwig, H. et al. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, pp. 12-20.
14. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. Carbone, D. P. et al. (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol, 160, pp. 1224-1232.
15. Treon, S. P., Maimonis, P., Bua, D., Young, G., Raje, N. Mollick, J. et al. (2000) Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 96, pp. 3147-3153.
16. Agrawal, B., Krantz, M. J., Reddish, M. A. and Longenecker, B. M. (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med, 4, pp. 43-49.
17. Gimmi, C. D., Morrison, B. W., Mainprice, B. A., Gribben, J. G., Boussiotis, V. A. Freeman, G. J. et al. (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med, 2, pp. 1367-1370.
18. Austyn, J. M. and Larsen, C. P. (1990) Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation, 49, pp. 1-7.
19. Zuniga, E. I., McGavern, D. B., Pruneda-Paz, J. L., Teng, C. and Oldstone, M. B. (2004) Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat Immunol, 5, pp. 1227-1234.
20. Reid, C. D., Fryer, P. R., Clifford, C., Kirk, A., Tikerpae, J. and Knight, S. C. (1990) Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood, 76, pp. 1139-1149.
21. Hock, B. D., Starling, G. C., Daniel, P. B. and Hart, D. N. (1994) Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology, 83, pp. 573-581.
22. Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P. Oliviero, B. et al. (2002) Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood, 100, pp. 230-237.
23. Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M. Miltenyi, S. et al. (2000) BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol, 165, pp. 6037-6046.
24. Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M. Gibson, J. et al. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood, 98, pp. 2992-2998.
25. Kovarova, L., Buchler, T., Pour, L., Zahradova, L., Ocadlikova, D. Svobodnik, A. et al. (2007) Dendritic cell counts and their subsets during treatment of multiple myeloma. Neoplasma, 54, pp. 297-303.
26. McKenna, K., Beignon, A. S. and Bhardwaj, N. (2005) Plasmacytoid dendritic cells: Linking innate and adaptive immunity. J Virol, 79, pp. 17-27.
27. Mason, D., Simmons, D., Buckley, C., Schwartz-Albiez, R., Hadam, M. Saalmuller, A. et al. (2002) Leukocyte typing VII. Oxford University Press, Oxford, UK
28. Glassman, A. B. and Bennett, C. E. (1977) B and T lymphocytes: methodology and normal ranges. Ann Clin Lab Sci, 7, pp. 519-523.
29. Reichert, T., DeBruyere, M., Deneys, V., Totterman, T., Lydyard, P. Yuksel, F. et al. (1991) Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol, 60, pp. 190-208.
30. Pilarski, L. M., Mant, M. J., Ruether, B. A. and Belch, A. (1984) Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J Clin Invest, 74, pp. 1301-1306.
31. Kay, N. E., Leong, T., Kyle, R. A., Greipp, P., Billadeau, D. Van Ness, B. et al. (1997) Circulating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood, 90, pp. 340-345.
32. Rasmussen, T., Jensen, L. and Johnsen, H. E. (2000) Levels of circulating CD19+ cells in patients with multiple myeloma. Blood, 95, pp. 4020-4021.
33. Schutt, P., Buttkereit, U., Brandhorst, D., Lindemann, M., Schmiedl, S. Grosse-Wilde, H. et al. (2005) In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: Influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunol Immunother, 54, pp. 506-512.
34. Pilarski, L. M., Masellis-Smith, A., Szczepek, A., Mant, M. J. and Belch, A. R. (1996) Circulating clonotypic B cells in the biology of multiple myeloma: Speculations on the origin of myeloma. Leuk Lymphoma, 22, pp. 375-383.
35. Gregersen, H., Madsen, K. M., Sorensen, H. T., Schonheyder, H. C., lbsen, J. S. and Dahlerup, J. F. (1998) The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol, 61, pp. 140-144.
36. Zhang, Z., Fu, J., Zhao, Q., He, Y., Jin, L. Zhang, H. et al. (2006) Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children after treatment with highly active antiretroviral therapy. J Immunol, 176, pp. 5644-5651.
37. Averill, L., Lee, W. M. and Karandikar, N. J. (2007) Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol, 123, pp. 40-49.
38. Harrison, S. J., Stewart, K., Holyoake, T. L., Franklin, I. M. and Fraser, A. R. (2003) Kinetics of circulating monocytoid dendritic cells in patients with hematological malignancies after allogeneic or autologous stem cell transplant. Blood, 102
39. Corral, L. G., Haslett, P. A., Muller, G. W., Chen, R., Wong, L. M. Ocampo, C. J. et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol, 163, pp. 380-386.
40. Schafer, P. H., Gandhi, A. K., Loveland, M. A., Chen, R. S., Man, H. W. Schnetkamp, P. P. et al. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther, 305, pp. 1222-1232.
41. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G. Tai, Y. T. et al. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, pp. 210-216.
42. Reddy, N., Cruz, R., Hernandez-Ilizaliturri, F., Knight, J. and Czuczman, M. S. (2006) Lenalidomide (Revlimid(R)) enhances monoclonal antibody-associated anti-tumor activity against rituximab-sensitive and rituximab-resistant B-cell lymphoma cell lines. ASH Annual Meeting Abstracts, 108, p. 2522.
43. Wu, L., Schafer, P., Muller, G., Stirling, D. and Bartlett, J. B. (2006) Lenalidomide strongly enhances natural killer (nk) cell mediated antibody-dependent cellular cytotoxicity (adcc) of rituximab treated non-Hodgkin's lymphoma cell lines in vitro. ASH Annual Meeting Abstracts, 108, p. 3714.
44. Mohty, M., Stoppa, A. M., Blaise, D., Isnardon, D., Gastaut, J. A. Olive, D. et al. (2002) Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol, 72, pp. 939-945.
45. Subklewe, M., Sebelin-Wulf, K., Beier, C., Lietz, A., Mathas, S. Dorken, B. et al. (2007) Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol, 68, pp. 147-155.
46. Straube, C., Wehner, R., Wendisch, M., Bornhauser, M., Bachmann, M. Rieber, E. P. et al. (2007) Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia, 21, pp. 1464-1471.
47. Kukreja, A., Hutchinson, A., Mazumder, A., Vesole, D., Angitapalli, R. Jagannath, S. et al. (2007) Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications. Br J Haematol, 136, pp. 106-110.
48. Brogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F. Cohen, D. et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood, 109, pp. 1123-1130.
49. Nencioni, A., Beck, J., Werth, D., Grunebach, F., Patrone, F. Ballestrero, A. et al. (2007) Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res, 13, pp. 3933-3941.